Tracking Cathie Wood: Increasing positions in precision medicine and gene editing, while reducing holdings in synthetic biology and data analysis leaders

On Wednesday, August 12, 2026, the US stock market showed divergent trends. Tech stocks led the gains, with the Nasdaq rising 0.54% to close at 26,588.49; the S&P 500 edged up 0.26% to 7,748.50; while the Dow Jones Industrial Average slipped slightly by 0.04% to 53,770.27. The overall market maintained a volatile pattern at high levels.

Against this backdrop, ARK Invest concentrated its buying power on disruptive innovation sectors such as early-stage precision medicine, gene editing, and cloud security on the day. Meanwhile, it rebalanced positions in certain synthetic biology stocks and tech stocks that had seen significant gains, demonstrating a strategic layout that balances offense and defense.

Buy Direction: Deepen the moat in precision medicine, while also covering cloud security and gene editing

$Freenome (FRNM.US)$ Purchased 190,403 shares on the day, marking the largest buy order. Freenome focuses on early cancer screening technology based on liquid biopsy. If its multi-cancer early detection platform achieves regulatory breakthroughs, it could redefine the underlying logic of oncology diagnostics. This move may reflect ARK's long-term bet on the rapid increase in early penetration rates of precision medicine.

$Cerus (CERS.US)$ Purchased 93,956 shares. Cerus's pathogen inactivation technology has established certain competitive barriers in the field of blood safety, and the global promotion of its INTERCEPT Blood System is still in a growth phase. ARK's increased holdings this time may indicate optimism about its market expansion potential against the backdrop of tightening global blood safety regulations.

$Cloudflare (NET.US)$ Purchased 31,974 shares. As a core holding in zero-trust cybersecurity architecture, Cloudflare continues to see strong demand amid accelerating enterprise digital transformation. ARK's additional investment suggests optimism about its potential to benefit from a new surge in demand for AI-driven cybersecurity.

$Intellia Therapeutics (NTLA.US)$ Purchased 13,390 shares. Intellia is one of the pioneers in in vivo CRISPR gene editing, with its pipeline assets attracting significant industry attention for progress in treating rare diseases. ARK's increased holdings may be a strategic addition amid rising expectations for catalysts in the gene editing sector recently.

$Schrodinger (SDGR.US)$ Purchased 9,356 shares. Schrödinger combines computational chemistry with AI for drug discovery, possessing differentiated competitiveness in the fast-growing niche of AI-driven pharmaceuticals. ARK's increased holdings in this target may reflect continued optimism about the long-term theme of AI accelerating new drug R&D efficiency.

Sell Side: Primarily focused on portfolio rebalancing to reduce concentration in certain high-weight positions.

$Twist Bioscience (TWST.US)$ Reduced holdings by 47,842 shares, marking the largest sell order of the day. As a synthetic biology infrastructure provider, Twist has seen recent stock price performance driven by industry hype. ARK's reduction in holdings is speculated to be for portfolio rebalancing, reallocating capital to earlier-stage targets with more attractive valuations.

$10x Genomics (TXG.US)$ Reduced holdings by 23,174 shares. 10x Genomics holds an important position in the field of single-cell genomics, but its commercialization progress may face certain pressures. This reduction may reflect ARK's cautious assessment of its short-term business progress or be part of overall portfolio optimization.

$Shopify (SHOP.US)$ Reduced holdings by 17,025 shares. As a leader in e-commerce infrastructure, Shopify holds a certain weight in ARK's portfolio. This position adjustment may aim to reduce concentration in mature tech stocks and redirect capital into earlier-stage targets with greater disruptive innovation potential.

$Palantir (PLTR.US)$ Reduced holdings by 11,134 shares. Palantir has recently performed strongly in the AI government and enterprise data analytics market, with its valuation continuing to expand. ARK's slight reduction in holdings is speculated to be reasonable position management given the elevated valuation.

$Brera Holdings (SLMT.US)$ Reduced holdings by 6,604 shares. This position is relatively small within ARK's portfolio, so this reduction may be part of routine portfolio optimization.

$Deere (DE.US)$ Reduced holdings by 3,932 shares. As a giant in agricultural machinery, Deere has relatively low alignment with ARK's core investment theme of disruptive innovation. This reduction likely reflects ARK's ongoing streamlining as it focuses on its core sectors.

$Snowflake (SNOW.US)$ Reduced holdings by 94 shares,$Strata Critical Medical (SRTA.US)$ Reduced holdings by 49 shares. Both transactions are symbolic minor adjustments, likely representing daily fine-tuning of the fund's positions with limited strategic significance.

Futubull’s [Opportunities Page] now features celebrity portfolio tracking! Choose from multiple celebrity holdings, follow top investors’ moves with one click, precisely target quality stocks, and invest with greater confidence!

131K Views